Screener
ADMA Biologics ADMA Plasma Collection Centers — D&A
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| (in thousands) | ADMA Bio Manufacturing | Plasma Collection Centers | Total |
|---|---|---|---|
| Plasma center operating expenses | - | 1,026 | 1,026 |
| Gain on sale of plasma centers | - | - | - |
| Selling, marketing and distribution | 7,634 | - | 7,634 |
| Depreciation and amortization expense | 1,281 | 499 | 1,780 |
| General and administrative expense | 8,340 | - | 8,340 |
| Other income (expense), net | (20) | 150 | 130 |
| Income (loss) before taxes | 64,010 | (707) | 63,303 |
| Expenditures for additions to long-lived assets | 2,256 | - | 2,256 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's plasma collection centers — D&A?
- ADMA Biologics (ADMA) reported plasma collection centers — D&A of $499K in Q2 2026.
- What is the long-term trend for ADMA Biologics's plasma collection centers — D&A?
- Over 3 years (2021 to 2024), ADMA Biologics's plasma collection centers — D&A has grown at a 23.7% compound annual growth rate (CAGR), from $1.27M to $2.41M.
- What does plasma collection centers — D&A mean?
- Represents the systematic allocation of the cost of tangible assets, such as collection equipment and facilities, and intangible assets over their useful lives. This non-cash expense reflects the capital intensity of maintaining a network of plasma centers. It is a key component in calculating the segment's cash flow generation.
Ask your AI about ADMA Biologics's plasma collection centers — d&a.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude